Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
HOME > REGULATORY
REGULATORY
- MHLW Panel OKs Celgene’s Apremilast, 2 Other NMEs
November 25, 2016
- MHLW Looks to Extend MID-NET to Cover Clinic Data: Bureau Chief
November 25, 2016
- More Patient Participation Needed to Promote Drug Development, Safety Measures: MHLW Official
November 25, 2016
- Keytruda Clears MHLW Panel for Both 1st-Line, 2nd-Line NSCLC
November 25, 2016
- Polaprezinc Ordered to Add Copper Deficiency in ADR List
November 24, 2016
- LDP’s Health Committee Demands Enhanced R&D Tax Break as Key Priority
November 24, 2016
- MHLW OKs Janssen’s HIV Combo Pill Prezcobix
November 24, 2016
- AMED to Allocate 240 Million Yen for R&D of Innovative Cancer Treatments, Including CAR-T Cell Therapy
November 24, 2016
- MHLW to Announce Opdivo’s New Prices on Nov. 24
November 24, 2016
- MHLW to Revise Rules on Development Requests for Unapproved Drugs
November 22, 2016
- Council OKs Public Knowledge-Based Application for Tamiflu’s New Pediatric Dosage
November 22, 2016
- MHLW to Set Up Quake-Resistant Warehouse to Stockpile Vaccines Using Supplementary Budget for FY2016
November 21, 2016
- MHLW to Kick Off Discussions for Major Drug Pricing Overhaul by Year-End: Bureau Chief
November 18, 2016
- MOF Panel Budget Recommendation Calls for Curbing Drug Costs
November 18, 2016
- 10 APIs/17 Products to Join NHI Price List on Nov. 18
November 17, 2016
- Chuikyo Floats Reimbursement Claims Based on “Amount Used” in Lieu of “Vial Units”
November 17, 2016
- Doctor, Industry Reps Get in Spat over Indication Additions: Chuikyo
November 17, 2016
- 50% Price Cut for Opdivo OK’ed with Estimated Sales of 151.6-Plus Billion Yen
November 17, 2016
- ICH Eyes Major GCP Revamp with Use of Real World Data: Osaka Confab
November 16, 2016
- 3 Immunosuppressants to Be Discussed for Lifting of Contraindicated Pregnancy Use
November 16, 2016
ページ
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…